


Available online on 15.06.2023 at <http://ajprd.com>

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

© 2013-22, publisher and licensee AJPRD, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Review Article

An Overview on Antifungal Drug Therapy

Mayuri More *, Prakash Jadhav, Ashish Bhongale, Atish Velhal, Vivek Kumar Redasani, Nishigandha Naikawadi

YSPM's, YTC Faculty of Pharmacy wadhe Phata Satara, Maharashtra, India

ABSTRACT

Nowadays, the majority of fungal infections, including candidiasis, can cause anything from a minor mucous membrane infection to fatal systemic mycoses. Due to the most rapid increase in populations with impaired hosts, such as those with HIV/AIDS, organ transplant recipients, and chemotherapy patients, candida infections present a serious clinical challenge internationally. In addition, a dramatic rise in the number of elderly people who are vulnerable to fungal infections is anticipated in the next decades. Due to the eukaryotic structure of the cells, developing antifungal medications for these issues is more challenging than developing antibacterial medications. Therefore, there are now only a limited number of antifungal medications available to treat the wide range of fungal infections. Additionally, the antifungal arsenal against fungal diseases has been constrained by the rise in antifungal resistance and unfavourable host effects.

Keywords: Antifungal, Candidiasis, Fungal Infections, Cutaneous Candidiasis, Athlete's Foot

ARTICLE INFO: Received 26 Feb.2023; Review Complete 27 April 2023; Accepted 29 May 2023; Available online 15 June 2023



Cite this article as:

More Mayuri, Jadhav Prakash, Bhongale Ashish, Velhal Atish, Redasani VK, Naikawadi N, Asian Journal of Pharmaceutical Research and Development. 2023; 11(3):-194:200, DOI: <http://dx.doi.org/10.22270/ajprd.v11i3.1270>

*Address for Correspondence:

Mayuri More, YSPM's, YTC Faculty of Pharmacy wadhe Phata Satara, Maharashtra, India

Antifungal-The pharmaceuticals used to treat fungi infections are known as antifungal drugs. Antifungal medications are available for oral consumption, topical use, and intravenous drip administration.

Activity of antifungal drug

Antifungal drugs often operate by either killing the fungus or preventing it from developing and proliferating. The fungal cell membrane and the fungal cell wall are among the components of the cell that the antifungal medications target. Both of these cell defence mechanisms have the potential to be damaged, causing the cell to leak and perish. Antifungal medications can target the fungi without hurting the body's cells because human bodies lack these structures.

TYPES OF FUNGAL INFECTIONS

The most common types of fungal infection are:

Ringworm: Other names for ringworm are tinea and dermatophytosis. It is a typical fungal skin illness that can be brought on by any of about 40 different fungi species.

Anywhere on the skin, including the scalp and feet, can develop it.

Oral thrush: This infection is brought on by yeast called Candida and happens when the environment in the mouth, throat, or oesophagus is disturbed. **Vaginal yeast infection:** The yeast that often resides in the body and on the skin is what causes vaginal yeast infection. Yeast can grow and lead to an infection if something disturbs the environment inside the vagina. **Onychomycosis:** While fungus can infect the nails of the hands as well, toenails are the most frequently affected. These infections are brought on by fungi when they get into the nail via tiny fissures in the nail or the surrounding skin. **Coccidioidomycosis:** Coccidioidomycosis, or valley fever, is a disease that is brought on by a fungus that inhabits the soil in the southwest of the United States.

There are some more serious infections that fungi can cause, and these include:

1. Aspergillosis
2. Blastomycosis
3. Cryptococcus Gattii Infection

4. Fungal Meningitis
5. Fungal Pneumonia
6. Histoplasmosis
7. Mucormycosis
8. Paracoccidioidomycosis
9. Talaromycosis

These are much rarer, but can be a lot more serious.

Ringworm: A ring-shaped rash and itchy, red, scaly, and cracked skin are the symptoms of this. Ringworm may result in a person losing their hair, depending on where it is located.

Oral thrush: The tongue and the interior of the mouth and throat may both have white spots. Redness could also be present. When swallowing or eating, a person could feel pain.

Jock itch: Those who have jock itch may experience red, scaly, and itchy patches, mainly on the inner sides of the thigh skin folds.

Athlete's foot: Athlete's foot patients may have red, swollen, itchy, and occasionally peeling skin between their toes.

Vaginal yeast infection: Symptoms can include painful urination, painful penetrative intercourse, discomfort, and abnormal vaginal discharge.

Onychomycosis: Thick, discoloured nails on the hands or feet of people with fungal infections are common. They could also be brittle or chipped.

Coccidioidomycosis: In addition to weariness, muscle aches, a headache, shortness of breath, and night sweats are also symptoms of valley fever. In addition, they might experience a rash and cough.

Following are some images that shows fungal infections



Figure 1: A. Cutaneous Candidiasis B. Ringworm C. Athlete's Foot (Tinea Pedis) D. Onychomycosis (Tinea Unguium)

Cutaneous Candidiasis-

A yeast infection of the skin called cutaneous candidiasis is brought on by the candida fungus. Among fungus, there is Candida. In warm, moist places of the skin, this form of fungus prefers to thrive. Candida infections can develop on the skin in a variety of locations, such as the diaper rash area on newborns' buttocks, under the nails, on the corners of the mouth, in the mouth lining, and on the skin around the nails. Yeast overgrowth is what causes cutaneous candidiasis. Obesity, smoking, and drinking alcohol are risk factors that can result in candida infection. Having diabetes. Utilising chemotherapy, steroid, and/or antibiotic treatments to combat cancer. The most typical sign of cutaneous candidiasis is an itchy rash that develops on the genitalia, skin folds, or other parts of the body.

Depending on where the cutaneous candidiasis resides, the course of treatment may differ.

Ringworm of the Scalp (Tinea Capitis)-

As the name suggests, ringworm of the scalp is a particular kind of fungal infection that affects the scalp, the skin that covers the top of the head. The entire scalp may occasionally be affected. Sometimes it affects just a portion of it.

Symptoms of ringworm of the scalp (also called tinea capitis) include:13

- Hair that has broken off, causing bald spots and sometimes long-term hair loss and scars
- Itchiness
- Low-grade fever
- Skin areas on the scalp that are red or swollen
- Sores filled with pus
- Enlarged lymph nodes on the neck

Ringworm of any type can spread quickly from person to person or from pets (especially cats) to people. Some

factors that increase the risk of ringworm of the scalp include

- Minor skin or scalp injuries
- Sweating for a long time, which creates wet skin on the scalp
- Using or touching items like combs or hats that also have been used by someone with ringworm
- Treatment for ringworm of the scalp is a prescription medication used for one to two months. Your healthcare provider also may recommend.

Athlete's Foot (Tinea Pedis)-

A fungus that frequently develops in the area between the toes is the root of athlete's foot, also known as tinea pedis. Athlete's foot can spread on wet surfaces in: using a medicated shampoo containing selenium sulphide or ketoconazole, which may prevent or delay the onset of an infection

examining and treating pets and other family members for scalp ringworm

- Locker rooms
- Public showers
- Swimming pools

Types of athlete's foot include

Chronic interdigital-which occurs in the webbed space between the fourth and fifth toes

Moccasin- which causes scaly skin on the soles of your feet and sometimes the hands Acute vesicular-It is unusual and begins with a long-term infection between your toes and may spread to the soles of your feet or other parts of your body.

Symptoms of athlete's foot usually occur between the toes. Symptoms include

- Burning of the skin
- Cracked skin
- Itchy skin
- Peeling skin
- Redness
- Scaly skin

Treatment for athlete's foot most commonly includes OTC antifungal powders or sprays. Athlete's foot. A more severe case may need prescription cream or oral pills.

Onychomycosis (Tinea Unguium)-Another word for a fungus nail infection is onychomycosis. Although fingernails can also be impacted, toenails are more frequently affected. This is also referred to as tinea unguium.

The risk of getting a fungal nail infection increases if you have moist nails for a lengthy period of time, particularly from sweating.¹⁸ You could potentially contract a fungal nail infection if you are barefoot and enter an area (like a locker room or pool) where someone else who has the condition has been.

A fungal nail infection can easily spread from one nail to the others

Symptoms of a fungal nail infection include

- Yellow nails
- Nails that are white or brown
- Nails that are loose and thin. It is also possible that the affected nails will thicken.
- Nails that crumble or split off

If your condition is mild, your doctor might begin treating you by putting medication right under your nails. Prescription antifungal medications are typically the best therapeutic option for situations that are more severe.²⁰ Health professionals might remove the nail in a severe case. It can take four to six months for fingernails and 12 to 18 months for toenails to recover from a fungal nail infection.

Antifungal drugs come in many forms depending on many factors. Specific drugs come in different forms. The type of infection a person has will impact how they receive the drugs.

There are four main types of antifungal drugs.

1. Polyenes
2. Azoles
3. Allylamines
4. Echinocandins

1. Polyenes-

These function by causing the fungal cells' walls to become more porous, increasing the likelihood that they may rupture.

Examples of polyenes and the fungal conditions they treat include:

Nystatin: A topical and oral antifungal that treats candida infections involving the mouth or skin. Amphotericin B: Treats a wide variety of fungal conditions, including invasive aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, cryptococcal meningitis, cryptococcosis, histoplasmosis, mucormycosis, sporotrichosis, and others.

2. **Azoles:** Two subcategories of azole antifungal drugs—imidazoles and triazoles—are present within this class.

Some examples of imidazoles and the fungal conditions they treat include:

- Clotrimazole: Skin, oral, and vaginal candida infections.
- Ketoconazole: Systemic fungal infections due to candida, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
- Miconazole: Vaginal, skin, and nail infections.

Some examples of triazoles and the fungal conditions they treat include:

- Fluconazole: Used for the treatment of fungal infections due to candida and cryptococcus.

- Isavuconazole: Treatment of invasive aspergillosis and mucormycosis infections.
 - Itraconazole: Blastomycosis, aspergillosis, histoplasmosis, candidiasis, and various superficial mycoses.
 - Posaconazole: Treats invasive fungal infections due to aspergillosis and candida.
 - Voriconazole: Aspergillosis and candida.
3. **Allylamines:** In order for the membrane of the cell to function properly, an enzyme is inhibited by allylamines. The cell would probably not be able to function without this membrane.

An example of an allylamine is terbinafine, which treats fungal skin infections.

4. **Echinocandins:** These prevent an enzyme from producing the fungal cell wall.

Some examples of echinocandins and the fungal conditions they treat include:

- Anidulafungin: Treats esophageal candidiasis and invasive candidiasis.
- Caspofungin: Aspergillosis, esophageal candidiasis, and invasive candidiasis.

Micafungin: Esophageal candidiasis and invasive candidiasis




Figure.2: Clinically used antifungals can be classified according to their mechanism of action.

A fungus can be killed with antifungal medications. Alternately, they could prevent it from spreading or expanding. Antifungal medications are divided into various classes and are available in various forms. The most effective prescription medication will be chosen by your healthcare professional. Alternatively, they might direct you towards an efficient over-the-counter (OTC) remedy.

Options include:

- Azoles (fluconazole or Diflucan®), synthetic (human-made) antifungals that keep fungi from growing.
- Echinocandins (micafungin or Mycamine®), newer semi-synthetic antifungals that attack and damage the fungus wall.
- Polyenes (nystatin or Bio-Statin®), organic (naturally occurring) antifungal treatments that destroy the fungus cell.

Particularly in populations with impaired immune systems, invasive fungal infections are a major cause of human mortality and morbidity. Over 1 million people die from fungus-related causes each year, including *Aspergillus fumigatus*, *Candida albicans*, and

Cryptococcus neoformans. There has never been a time when safe and efficient antifungal therapies were more crucial for the practise of modern medicine. The number of distinct molecular targets that can be used for medication development is still constrained because fungi are eukaryotes, just like their human host. For the time being, only three chemical classes have been approved to treat invasive mycoses. Host toxicity, fungistatic action, or the development of drug resistance in pathogen populations all reduce the effectiveness of these medications. Here, we outline the antifungal drugs in our arsenal at the moment and emphasise current strategies that are being employed to improve the therapeutic safety and efficacy of these drugs.

MECHANISM OF ACTION

Cell membrane rupture is the primary mechanism of action for topical antifungal medications. Antifungal medications, particularly those that contain ergosterol, frequently target the distinctive elements found in the membranes of fungal cells. It is a sterol, which is crucial for maintaining adequate membrane fluidity and the correct operation of the cell membrane. In the cell membranes of mammalian cells, ergosterol takes the role

of cholesterol. Antifungal drugs that target ergosterol synthesis are specifically harmful to fungi, killing and halting fungus growth in the body. Ergosterol damage results in the contents of the fungal cells leaking out, inhibiting the growth of new fungal cells. The mortality of fungal cells is also influenced by antifungal substances.

Dermatophytes, yeasts, and moulds frequently cause fungal infections. Yeasts are natural skin dwellers, but occasionally they can proliferate unchecked and cause infections with visible symptoms. Although moulds are a rare source of fungal infections, they can result in tinea nigra, which creates painless brown or black patches on the skin, or difficult-to-treat nail infections. Pityriasis capitis (dandruff) is a typical illustration of a fungus infection. Oral candidiasis (oral thrush), onychomycosis

(nail infection), tinea pedis (athlete's foot), Pityriasis Versicolor, tinea capitis, tinea corporis (ringworm), tinea cruris (jock itch), and tinea manuum are some examples of common skin conditions. Most antifungal medications deal with both yeast and dermatophyte infections. But some of them—like nystatin—are ineffective against dermatophyte fungal infections. As a result, many antifungals can eradicate fungal diseases from the host while causing the least amount of toxicity.

Topical antifungals can be used safely by adults, children, and those with reduced mobility. Patients with different age groups may need different dosages. Before using topical antifungal medications, consult with a healthcare practitioner.




Figure.3: Structures and mechanisms of action of clinically relevant antifungal drugs.

- A. The azoles work by inhibiting the ergosterol biosynthetic enzyme lanosterol demethylase, which is encoded by the genes *cyp51A* and *cyp51B* (in *A. fumigatus*) or *ERG11* (in *Candida albicans* and *Candida neoformans*). This results in an accumulation of a toxic sterol generated by *Erg3* and a halt in ergosterol synthesis. The cell's membrane is severely stressed by this poisonous sterol.
- B. Large extra membranous aggregates are the main form of polyenes like amphotericin B, which remove ergosterol from lipid bilayers.
- C. Chitin, mannans, and cell wall proteins are found in addition to (1, 3)-d-glucans that are covalently connected to (1, 6)-d-glucans. The echinocandins cause severe cell wall stress and a loss of cell wall integrity by acting as noncompetitive inhibitors of (1, 3)-d-glucan synthase (encoded by *FKS1* in *C. albicans*, *C. neoformans*, and *A. fumigatus*).
- D. Fungal-specific cytosine deaminases quickly deaminate pyrimidines, like flucytosine, in the cytosol to produce 5-fluorouracil (5-FU). A strong antimetabolite, 5-FU disrupts DNA synthesis and leads to RNA miscoding. Adapted with permission from reference 185.

SIDE EFFECTS

Topical antifungals can have negative effects, but not everyone will. The following are a few of the most typical negative effects:

1. Burning or stinging
2. Rash
3. Sensitivity reactions
4. Skin irritation (redness, peeling, and swelling).

5. Some vaginal topical antifungal preparations have been associated with burning, cramping, itching, pain, and bleeding.

AVAILABLE FORMULATIONS IN MARKET

Antifungal medications come in different forms such as:

1. Topical Antifungals – Creams, Gels, Ointments, Sprays Or Shampoos That You Put On Your Skin
2. Oral Antifungals – Capsules, Tablets Or Liquids That You Swallow
3. Antifungal Pessaries – Small, Soft Tablets That You Put Inside Your Vagina
4. Intravenous (Iv) Antifungals – Injections Into Your Arm

Cell membrane rupture is the primary mechanism of action for topical antifungal medications. Antifungal medications, particularly those that contain ergosterol, frequently target the distinctive elements found in the membranes of fungal cells. It is a sterol, which is crucial for maintaining adequate membrane fluidity and the correct operation of the cell membrane. In the cell membranes of mammalian cells, ergosterol takes the role of cholesterol. Antifungal drugs that target ergosterol synthesis are specifically harmful to fungi, killing and halting fungus growth in the body. Ergosterol damage results in the contents of the fungal cells leaking out, inhibiting the growth of new fungal cells. Last but not least, antifungal drugs cause the death of fungal cells.

For topical antifungal medicines, cell membrane disruption is the main mode of action. The unique components present in the membranes of fungus cells are typically the target of antifungal drugs, especially those containing ergosterol. It is a sterol, which is important for preserving proper membrane fluidity and the proper functioning of the cell membrane. Ergosterol replaces cholesterol in the cell membranes of mammalian cells. Antifungal medications that target the synthesis of ergosterol are specifically damaging to fungi, killing them and preventing their proliferation in the body. Ergosterol damage causes the fungal cells' contents to leak out, which prevents the development of new fungal cells. Last but not least, antifungal medications kill fungus cells.

Dermatophytes, yeasts, and moulds frequently cause fungal infections. Yeasts are natural skin dwellers, but occasionally they can proliferate unchecked and cause infections with visible symptoms. Although moulds are a rare source of fungal infections, they can result in tinea nigra, which creates painless brown or black patches on the skin, or difficult-to-treat nail infections. Pityriasis capitis (dandruff) is a typical illustration of a fungus infection. Oral candidiasis (oral thrush), onychomycosis (nail infection), tinea pedis (athlete's foot), Pityriasis Versicolor, tinea capitis, tinea corporis (ringworm), tinea cruris (jock itch), and tinea manuum are some examples of common skin conditions. Most antifungal medications deal with both yeast and dermatophyte infections. But some of them—like nystatin—are ineffective against

dermatophyte fungal infections. As a result, many antifungals can eradicate fungal diseases from the host while causing the least amount of toxicity.

Topical antifungals can be used safely by adults, children, and those with reduced mobility. Patients with different age groups may need different dosages. Before using topical antifungal medications, consult with a healthcare practitioner.

GENERAL PRECAUTIONS

Wash the afflicted area with soap and water and properly dry it before using topical antifungals. After using topical products, carefully wash both hands. Topical antifungals should be applied in a thin layer to the infected area. If a clinician doesn't specifically instruct you otherwise, avoid utilising occlusive dressings or wrappings.

Typically, topical antifungal medicines have negative effects. After using these products, some individuals may experience localised irritability or itching. If the treated region displays symptoms like erythema, pruritus, burning, blistering, swelling, or leaking, you should speak with a chemist or medical professional. Food and other medications, as well as these drugs, can interact. Let chemists or doctors know about any concurrent therapies that are now being used or are being considered, including prescription and OTC medications, dietary or herbal supplements, and any concurrent illnesses. Consequently, topical antifungals should only be applied after consulting a physician.

REFERENCE

1. Antifungal Drugs: The Current Armamentarium and Development of New Agents Authors: Nicole Robbins, Gerard D. Wright, Leah E. Cowen, ASM Journals Microbiology Spectrum Vol. 4, No. 5 Antifungal Drugs: The Current Armamentarium and Development of New Agents.
2. McKenry, Patrick T.; Nessel, Trevor A.; Zito, Patrick M., "Antifungal Antibiotics", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 30844195, retrieved 2022-04-23
3. Scorzoni, Liliana; de Paula e Silva, Ana C. A.; Marcos, Caroline M.; Assato, Patrícia A.; de Melo, Wanessa C. M. A.; de Oliveira, Haroldo C.; Costa-Orlandi, Caroline B.; Mendes-Giannini, Maria J. S.; Fusco-Almeida, Ana M. (2017). "Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis". *Frontiers in Microbiology*. 8: 36. doi:10.3389/fmicb.2017.00036. ISSN 1664-302X. PMC 5253656. PMID 28167935.
4. Kelemen, H.; Orgovan, G.; Szekely-Szentmiklosi, B. "[The pharmaceutical chemistry of azole antifungals.]. *Acta Pharmaceutica Hungarica*.2016; 86 (3): 85–98. ISSN 0001-6659. PMID 29489080.
5. Benitez, Lydia L.; Carver, Peggy L. "Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents". *Drugs*. 2019; 79 (8): 833–853. doi:10.1007/s40265-019-01127-8. ISSN 1179-1950. PMID 31093949. S2CID 155093431. "Azole - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2022-04-23.
6. Nocua-Báez, Laura Cristina; Uribe-Jerez, Paula; Tarazona-Guaranga, Leonardo; Robles, Ricardo; Cortés, Jorge A.; Nocua-Báez, Laura Cristina; Uribe-Jerez, Paula; Tarazona-Guaranga, Leonardo; Robles, Ricardo; Cortés, Jorge A. "Azoles of then and now: a review". *Revistachilena de infectología*. 2020; 37(3): 219–230. doi:10.4067/s0716-10182020000300219. ISSN 0716-1018. PMID 32853312. S2CID 225580512.

7. Prasad, Rajendra; Shah, Abdul Haseeb; Rawal, Manpreet Kaur , Ramos, José; Sychrová, Hana; Kschischo, Maik (eds.), "Antifungals: Mechanism of Action and Drug Resistance", Yeast Membrane Transport, Cham: Springer International Publishing, 2016; 892: 327–349, doi:10.1007/978-3-319-25304-6_14, ISBN 978-3-319-25304-6, PMID 26721281, retrieved 2022-04-23
8. Johnson, Melissa D. "Antifungals in Clinical Use and the Pipeline". Infectious Disease Clinics of North America. Fungal Infections. 2021; 35(2): 341–371. doi: 10.1016/j.idc.2021.03.005. ISSN 0891-5520. PMID 34016281. S2CID 235074214.
9. Antifungal Combinations against Candida Species: From Bench to Bedside. Fioriti S, Brescini L, Pallotta F, Canovari B, Morroni G, Barchiesi F.J Fungi (Basel). 2022 Oct 13; 8(10):1077
10. Pfaller, M.A. et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary Resistance using national committee for clinical laboratory standards Susceptibility testing methods. Antimicrob. Agents Chemother.2002; 46,3518–3521
11. Pfaller MA, Diekma DJ. Rare and emerging opportunistic fungal patho-Gens: concern for resistance beyond Candida albicans and AspergillusFumigatus. J Clin Microbiol 2004; 42: 4419-4431.
12. Pristov, K. E. & Ghannoum, M. A. Resistance of Candida to azoles and echinocandins worldwide. Clin. Microbiol. Infect. 25, 792–798 (2019).
13. Pfaller K., Alspaugh J.A. New Horizons in Antifungal Therapy. J. Fungi. 2016; 2:26. doi: 10.3390/jof2040026.
14. Brown G.D., Denning D.W., Gow N., Levitz S.M., Netea M., White T.C. Hidden Killers: Human Fungal Infections. Sci. Transl. Med. 2012; 4:165rv13. doi: 10.1126/scitranslmed.3004404.
15. Shapiro RS, Robbins N, Cowen LE. 2011. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev 75:213–267.

